Mr. Sam Rizkal
Chief Executive Officer
Monarch PCM, LLC
7333 Jack Newell Boulevard North Suite 100
Fort Worth , TX 76118
United States
alan.jones@monarchpcm.comFEI 3012816585Issued Jun 10, 2022Office of Pharmaceutical Quality Operations, Division II
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3012816585.
Violations8
Issue DateJun 10, 2022
Product TypeDrugs
StatusOpen
Letter Details
Firm
Monarch PCM, LLC
Location
Mr. Sam Rizkal
Chief Executive Officer
Monarch PCM, LLC
7333 Jack Newell Boulevard North Suite 100
Fort Worth , TX 76118
United States
alan.jones@monarchpcm.com
FEI Number
3012816585
Country
United States
Issue Date
June 10, 2022
Issuing Office
Office of Pharmaceutical Quality Operations, Division II
Product Type
Drugs
Status
Open
Summary
Monarch PCM, LLC, a drug manufacturer in Fort Worth, Texas, violated Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, resulting in its products being deemed adulterated. The company manufactured several unapproved new drugs including Hydroquinone USP 4% Skin Bleaching Cream, Sodium Sulfacetamide products, and Selenium Sulfide 2.25% Shampoo without proper FDA approval and failed to properly list certain products with the FDA as required. The inspection from June to August 2021 identified significant violations in the company's manufacturing methods, facilities, and controls that rendered its drug products non-compliant with federal regulations.
Monarch PCM, LLC FDA Warning Letter, June 10, 2022